DE69904010D1 - Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren - Google Patents

Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren

Info

Publication number
DE69904010D1
DE69904010D1 DE69904010T DE69904010T DE69904010D1 DE 69904010 D1 DE69904010 D1 DE 69904010D1 DE 69904010 T DE69904010 T DE 69904010T DE 69904010 T DE69904010 T DE 69904010T DE 69904010 D1 DE69904010 D1 DE 69904010D1
Authority
DE
Germany
Prior art keywords
vip
mammals
medicine
create
shocks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69904010T
Other languages
English (en)
Other versions
DE69904010T2 (de
Inventor
Gomariz Rosa Perez
Martinez Javier Leceta
Mora Mario Delgado
Mora Carmen Martinez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Complutense de Madrid
Original Assignee
Universidad Complutense de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Complutense de Madrid filed Critical Universidad Complutense de Madrid
Publication of DE69904010D1 publication Critical patent/DE69904010D1/de
Application granted granted Critical
Publication of DE69904010T2 publication Critical patent/DE69904010T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
DE69904010T 1998-04-17 1999-04-16 Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren Expired - Fee Related DE69904010T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009800814A ES2138561B1 (es) 1998-04-17 1998-04-17 Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos.
PCT/ES1999/000101 WO1999053944A1 (es) 1998-04-17 1999-04-16 Metodo para el tratamiento del 'shock' endotoxico en mamiferos

Publications (2)

Publication Number Publication Date
DE69904010D1 true DE69904010D1 (de) 2003-01-02
DE69904010T2 DE69904010T2 (de) 2003-08-21

Family

ID=8303495

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69904010T Expired - Fee Related DE69904010T2 (de) 1998-04-17 1999-04-16 Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren

Country Status (10)

Country Link
US (1) US6429188B1 (de)
EP (1) EP1002542B1 (de)
JP (1) JP2002507224A (de)
AT (1) ATE228006T1 (de)
AU (1) AU3148699A (de)
CA (1) CA2294980A1 (de)
DE (1) DE69904010T2 (de)
ES (1) ES2138561B1 (de)
PT (1) PT1002542E (de)
WO (1) WO1999053944A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074708A1 (es) * 1999-06-04 2000-12-14 Universidad Complutense De Madrid Metodo para el tratamiento del shock entotoxico y enfermedades inflamatorias y autoinmunes en mamiferos
WO2003096024A1 (en) * 2002-05-08 2003-11-20 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 2 (vpac2)
US7547450B2 (en) * 2002-10-24 2009-06-16 Nestec Ltd. Senior feline food
NZ537089A (en) 2003-02-24 2007-07-27 Morinaga Milk Industry Co Ltd Interleukin 6 production inhibitor
US8178495B2 (en) 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
ES2779992T3 (es) 2005-12-20 2020-08-21 Univ Duke Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas
WO2011020091A1 (en) * 2009-08-14 2011-02-17 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
WO2012170524A1 (en) 2011-06-06 2012-12-13 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
CA2947982C (en) 2014-05-08 2022-11-29 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
CN107427556B (zh) 2015-02-09 2022-02-25 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides

Also Published As

Publication number Publication date
CA2294980A1 (en) 1999-10-28
US6429188B1 (en) 2002-08-06
PT1002542E (pt) 2003-04-30
EP1002542A1 (de) 2000-05-24
JP2002507224A (ja) 2002-03-05
ATE228006T1 (de) 2002-12-15
ES2138561A1 (es) 2000-01-01
EP1002542B1 (de) 2002-11-20
ES2138561B1 (es) 2000-07-01
WO1999053944A1 (es) 1999-10-28
AU3148699A (en) 1999-11-08
DE69904010T2 (de) 2003-08-21

Similar Documents

Publication Publication Date Title
DE69904010D1 (de) Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren
DE69731540D1 (de) Behandlung von diarrhoe
DE69719408D1 (de) Verwendung von Strontiumsälze zur Behandlung von Arthrose
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DE69703649D1 (de) Behandlung von deagglomerierten teilchen mit plasmaaktivierter spezies
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
ATE110958T1 (de) Verwendung von sertralin zur behandlung verfrühter ejakulation.
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DK0637306T3 (da) 4-Imidomethyl-1-[2'-phenyl-2'-oxoethyl]-piperidiner som serotonin-5HT2-antagonister, deres fremstilling og anvendelse til terapi
ATE254924T1 (de) Stör-notokord zur verminderung der symptome / behandlung von arthritis
DE59202663D1 (de) Verwendung eines UV-Strahlers zur Behandlung von Oberflächen.
ATE106736T1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
ATE212845T1 (de) Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
ATE74762T1 (de) Pharmazeutisches praeparat zur behandlung von stoerungen des fettstoffwechsels (hyperlipoproteinaemien).
ATE69163T1 (de) Verwendung von oligopeptiden zur behandlung von cerebralen stoerungen.
DE3861494D1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
ATE83665T1 (de) Anwendung des humanblut-koagulationsfaktors-xiii zur behandlung von colitis gravis.
ATE229336T1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
DE69904712D1 (de) Verwendung von deltorphin zur behandlung von zytokin-vermittelter leberschädigung
DE68908404D1 (de) Lang haltende zusammensetzung von propafenon und chinidin zur behandlung des zustandes des herzens.
ATE229343T1 (de) Kombination von temozolomide und alpha-interferon zur behandlung von fortgeschrittenem krebs
DE69004267D1 (de) Glycyl-p-amino-pyridin zur behandlung von seniler demenz.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee